Abstract
In this ongoing study, substantially increased ancestral SARSCoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable.
Author supplied keywords
Cite
CITATION STYLE
Simões, E. A. F., Klein, N. P., Sabharwal, C., Gurtman, A., Kitchin, N., Ukkonen, B., … Sokolowska, A. (2023). Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. Journal of the Pediatric Infectious Diseases Society, 12(4), 234–238. https://doi.org/10.1093/jpids/piad015
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
